ES2B-C001

Bent U Frandsen, CEO of Expres2ion Biotech at BIO-Europe

ExpreS2ion CEO talking about partnering efforts at BIO-Europe

Heading towards phase I studies with breast cancer vaccine candidate ES2B-C001, ExpreS2ion Biotech is actively looking for partners. Also,...

BioStock TV
Intervju
Expres2ion to raise SEK 60 million

Rights issue takes Expres2ion breast cancer vaccine to phase I

Having validated its vaccine platform in Covid-19, Expres2ion...
Bent U. Frandsen, CEO ExpreS2ion Biotechnologies

ExpreS2ion CEO: “Compelling preclinical package gives us confidence”

Based on its proprietary protein expression platform, ExpreS2ion...

Intervju
Bent U. Frandsen, CEO ExpreS2ion Biotech talks about the development and the rights issue

ExpreS2ion CEO comments ongoing rights issue

ExpreS2ion Biotechnologies has a broad portfolio of vaccine...

BioStock TV
Intervju
Bent U. Frandsen, CEO ExpreS2ion Biotechnologies

BioStock Investor Pitch: ExpreS2ion Biotechnologies

Danish ExpreS2ion Biotechnologies develops a portfolio of vaccines...

BioStock TV
ExpreS2ion Biotech is looking forward to multiple milestones

Multiple near-term milestones for ExpreS2ion Biotechnologies

With an upcoming phase III readout and ongoing...
Bent U. Frandsen, CEO ExpreS2ion Biotechnologies

ExpreS2ion’s CEO on current development and the rights issue

ExpreS2ion Biotechnologies is eagerly awaiting top-line results from

Intervju
ExpreS2ion vaccine

Emission avancerar ExpreS2ions vaccinkandidater

Bioteknikbolaget ExpreS2ion Biotech flyttar fram sin position på...
ExpreS2ion lab

ExpreS2ions vd om emissionen och vaccinutvecklingen

Samtidigt som fas III-studien med covid-19-vaccinet ABNCoV2 förbereds...

Intervju
BENT U FRANDSEN

BioStock Investor Pitch: ExpreS2ion Biotechnologies

Bioteknikbolaget ExpreS2ion Biotechnologies utvecklar proteinbaserade vacciner med sin...

BioStock TV